AnorMed begins multiple myeloma trial

AnorMed reports that it has enrolled 300 patients in a phase 3 study of Mozobil in stem-cell transplant for multiple myeloma.

The most recently enrolled patients will receive stem cell transplants over the next four to six weeks, with a subsequent 100-day follow-up period.

Investigators then have up to six months from the first transplant to perform a second or "tandem" transplant if needed, with a 100-day follow-up after the second transplant, AnorMed said.